SCHEMBL3499323

SCHEMBL3499323

CCCc1c(C(=O)O)oc2cc(-c3ccc(Cl)cc3)ccc12

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 7/20 0.50
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP19A1 P11511 1/20 0.39
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B3 P37058 1/20 0.38
CTRC Q99895 1/20 0.38
ALAD P13716 1/20 0.38
TTR P02766 1/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
PTGER4 P35408 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498194 0.89 MCL1 (0.40) MCL1MEN1KMT2AESR1ESR2
SCHEMBL3498198 0.89 KDM4E (0.43) MCL1ESR1ESR2KDM4ECYP19A1
SCHEMBL3498486 0.85 KDM4E (0.47) MCL1KDM4E
SCHEMBL3498674 0.83 GCG (0.41) MCL1POLB
SCHEMBL3498622 0.81 KMT2A (0.41) MEN1KMT2AESR1ESR2CYP19A1
SCHEMBL3498475 0.80 MCL1 (0.78) MCL1MEN1KMT2AKDM4EMAPK1
SCHEMBL3499188 0.79 MAPT (0.41) MEN1KMT2AKDM4ENPC1RAB9A
SCHEMBL3498789 0.78 DGAT1 (0.43) MEN1KMT2ANPC1RAB9A
SCHEMBL3498788 0.78 DGAT1 (0.43) MEN1KMT2ANPC1RAB9A
SCHEMBL3501302 0.78 ALDH1A1 (0.44) MEN1KMT2AMAPK1CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MCL1 3727/4885MEN1 3918/4885KMT2A 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.